Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESSION: Combination vs Switch vs Monotherapy in Progressive IPF
NCT03939520Phase 4Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2020
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pirfenidone and nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Hospices Civils de Lyon. Started Jun 2020; status: completed.
02
Drugs
pirfenidonenintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03939520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939520.